Scott B Robbins

US Patent:

20120263754, Oct 18, 2012

Filed:

Feb 15, 2012

Appl. No.:

13/397216

Inventors:

Jared M. Odegard - Seattle WA, US
Scott H. Robbins - Lake Forest Park WA, US

Assignee:

IMMUNE DESIGN CORP. - Seattle WA

International Classification:

A61K 31/7088
A61P 35/00
A61P 33/00
A61P 31/04
A61P 31/10
A61P 37/04
A61P 31/12

US Classification:

4242041, 4242781, 4242771, 4242341, 4242741, 4242651, 4242831

Abstract:

Provided herein are methods for inducing a specific immune response in a subject by administering to the subject an immunogenic composition comprising a recombinant expression vector, or a vector particle comprising the recombinant expression vector, which vector comprises a polynucleotide sequence that encodes an immunogen of interest. The methods further comprise administering an adjuvant composition either concurrently or sequentially with the immunogenic composition.

US Patent:

20120288515, Nov 15, 2012

Filed:

Apr 27, 2012

Appl. No.:

13/458098

Inventors:

Scott H. Robbins - Lake Forest Park WA, US

Assignee:

IMMUNE DESIGN CORP. - Seattle WA

International Classification:

A61K 39/00
A61P 35/00
A61P 31/04
A61K 39/245
A61P 31/12

US Classification:

4241861, 4241851

Abstract:

Synthetic long peptides and an adjuvant are formulated together and administered to a subject in order to raise an immune response. In certain embodiments, the adjuvant is GLA.

US Patent:

20120328655, Dec 27, 2012

Filed:

Apr 6, 2012

Appl. No.:

13/441502

Inventors:

Scott H. Robbins - Lake Forest Park WA, US

Assignee:

IMMUNE DESIGN CORP. - Seattle WA

International Classification:

A61K 39/00
A61K 39/12
A61P 37/04
A61K 39/002
A61K 39/245
A61K 39/39
A61K 39/02

US Classification:

4242311, 4241841, 4242831, 4242771, 4242041, 4242341, 4242741, 4242651

Abstract:

Compositions and methods are provided herein for improved dual immunization strategies that induce in a subject an immune response that includes a humoral immune response and cellular immune response, both CD4 and CD8 T lymphocyte immune responses, thereby providing a complete adaptive immune response to one or more antigens. The methods described are therefore useful for treating and/or preventing (i.e., reducing the likelihood or risk of occurrence) different diseases, disorders, and conditions such as cancers and infectious diseases for which induction of both a humoral immune response and cellular immune response is desired and beneficial.

US Patent:

20200023057, Jan 23, 2020

Filed:

Jul 16, 2019

Appl. No.:

16/513311

Inventors:

- Seattle WA, US
Nancy A. Hosken - Seattle WA, US
Scott H. Robbins - Seattle WA, US
Margaret D. Moore - Seattle WA, US

International Classification:

A61K 39/245
C07K 14/005
A61K 39/12

Abstract:

Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects.

US Patent:

20170274066, Sep 28, 2017

Filed:

Dec 14, 2016

Appl. No.:

15/378864

Inventors:

- Seattle WA, US
Nancy A. Hosken - Seattle WA, US
Scott H. Robbins - Lake Forest Park WA, US
Margaret D. Moore - Seattle WA, US

Assignee:

IMMUNE DESIGN CORP. - Seattle WA

International Classification:

A61K 39/245
A61K 39/12
C07K 14/005
A61K 38/00
A61K 39/00

Abstract:

Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects.

US Patent:

20150335733, Nov 26, 2015

Filed:

Apr 27, 2015

Appl. No.:

14/696690

Inventors:

- Seattle WA, US
Scott H. Robbins - Lake Forest Park WA, US

International Classification:

A61K 39/245
A61K 39/00
A61K 39/12
A61K 39/39

Abstract:

Compositions and methods are provided herein for improved dual immunization strategies that induce in a subject an immune response that includes a humoral immune response and cellular immune response, both CD4 and CD8 T lymphocyte immune responses, thereby providing a complete adaptive immune response to one or more antigens. The methods described are therefore useful for treating and/or preventing (i.e., reducing the likelihood or risk of occurrence) different diseases, disorders, and conditions such as cancers and infectious diseases for which induction of both a humoral immune response and cellular immune response is desired and beneficial.

US Patent:

20140127247, May 8, 2014

Filed:

May 16, 2013

Appl. No.:

13/895858

Inventors:

- Seattle WA, US
Nancy A. Hosken - Seattle WA, US
Scott H. Robbins - Seattle WA, US
Margaret D. Moore - Seattle WA, US

Assignee:

IMMUNE DESIGN CORP. - Seattle WA

International Classification:

A61K 39/245

US Classification:

4241861

Abstract:

Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects.

US Patent:

20140086947, Mar 27, 2014

Filed:

May 16, 2013

Appl. No.:

13/895888

Inventors:

IMMUNE DESIGN CORP. - , US
Nancy A. Hosken - Seattle WA, US
Scott H. Robbins - Lake Forest Park WA, US
Margaret D. Moore - Seattle WA, US

Assignee:

IMMUNE DESIGN CORP. - Seattle WA

International Classification:

C07K 14/005
A61K 39/245

US Classification:

4241861, 530350, 536 234, 536 2372

Abstract:

Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects.